CIZ gene rearrangements in acute leukemia: report of a diagnostic FISH assay and clinical features of nine patients
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demonstrated for the first time in the CIZ gene was involved in leukemia. Patients 1-6 had a t(12;17)(p13;q11) which was isolated in five cases and associated with loss of chromosome Y in patient 1. Patients 7 and 8 had a t(12;22)(p13;q12) which was isolated in patient 7 and included in a complex karyotype in the other. In patient 9, a complex karyotype including an add(10)(p), a del(12)(p13), and trisomy 13 was found in 35% of metaphases (Table 1) . Table 2 shows the results of FISH studies on metaphase cells and interphase nuclei, which were performed with the 12p13 clones illustrated in Figure 1 . In all patients, the split-signal FISH assay detected CIZ rearrangements in 20-50% of interphase nuclei (Figure 2a ). The RP11-433J6 clone encompassed the 12p13 breakpoint giving three hybridization signals in 15-54% of interphase nuclei. In abnormal metaphases, it labeled the normal 12, the der(12) and der(17) (patients 1-6), der(22) (patients 7 and 8), or an apparently normal 19 (patient 9). Metaphase FISH narrowed the CIZ breakpoint to between probes 9.6 (5 0 CIZ) and 8.2 (3 0 CIZ) in patients 2-7, to within the sequence encompassed by 9.6 in patient 8, and to within that encompassed by 8.2 in patient 1 (Figure 2b and c). Surprisingly, the same probes showed that CIZ was rearranged with chromosome 19p13 in patient 9, who did not have the two typical CIZ translocations at karyotyping (Table 2 ; Figure 2d ).
In cases 1-6 with t(12;17), the RP11-689E22 clone identified the TAF15/17q11 breakpoint, giving three hybridization signals on normal 17, der(17), and der(12). In cases 7 and 8 with t(12;22), cosmid G9, mapping at the proximal side of EWSR1, and cosmid F7, mapping at the distal side of EWSR1, 2 detected the 22q12 breakpoint as G9 hybridized with the normal 22 and with der(22), and F7 hybridized with the normal 22 and with der(12).
In the search for the partner gene in patient 9, RP4-546C11, a clone for the subtelomeric region of 19p, hybridized to 19p13 and to der(12). The TCF3 FISH DNA probe (Dako Cytomation, Glostrup, Denmark) gave a red/green fusion signal on one chromosome 19p13, one red signal on the other and one green signal on der(12), confirming a t(12;19) and involvement of the TCF3/E2A gene, which has been already reported in a patient with ALL (Hunger SP, Zhang C. Blood 2002; 100). The TCF3/ E2A gene encodes for several transcription factors via alternative splicing and is involved in t(1;19)(q23;p13)-E2A/PBX1 in pediatric pre-B ALL where it may also rearrange with HLF and FB1 in the t(17;19)(q22;p13) and inv(19)(p13q13), respectively. CIZ emerges as the third transcription factor to be involved in TCF3/E2A fusion genes in ALL.
Our FISH assay identified the t(12;17)(p13;q11) and t(12;22)(p13;q12) translocations, which disrupt the CIZ gene. In all patients, PCR detected either the TAF15/CIZ or the EWSR1/CIZ, indicating that PCR and FISH are equivalent diagnostic tools for t(12;17)(p13;q11)-TAF15/CIZ and t(12;22)(p13;q12)-EWSR1/CIZ. FISH emerged, however, as a unique diagnostic assay for investigating as yet, unidentified rearrangements of CIZ with other chromosomal/gene partners and for unraveling its cryptic involvements.
Molecular evidence confirms cytogenetic findings of primary aberrations in seven of our nine patients supporting the hypothesis that CIZ involvement is a primary event with an early role in the leukemogenic pathway. MLL/AF4, BCR/ABL1 p190 and p210, E2A/PBX1, and ETV6/AML1 fusion proteins were normal in the four, five, two, and two patients we tested for each fusion gene. Interphase FISH was negative for rearrangements of P15/P16, ATM, D13S25, TP53, and AML1 CHT relapse 15d S ¼ sex; A ¼ age (in years); bulky ¼ hepatomegaly, splenomegaly, lymphoadenopathy, and central nervous system involvement; WBC ¼ white blood cells Â 10 9 /l; ALL ¼ acute lymphoblastic leukemia; AML ¼ acute myeloblastic leukemia;* ¼ follow-up in months; aBMT ¼autologous BMT; BMT ¼allogeneic bone marrow transplantation; CR ¼ complete remission; CHT ¼standard chemotherapy; d ¼ died; + ¼ alive; * the G-banding identified the t(12;19)(p13;p13) as del(12)(p13).
in patients 1-5 and 8. An Ikaros gene probe indicated chromosome 7 monosomy in 25% of nuclei only in patient 4, confirmed by D7Z1 (Oncor), a centromeric probe for chromosome 7.
CIZ rearrangements characterize a specific hematological/ genetic ALL subset with early-B phenotype, myeloid marker expression, no bulky disease, and onset in young adults and children. In fact, our patients had a median age of 22 years (range 2-44 years). Diagnosis was ALL in eight and, despite strong CD19 positivity, AML (FAB M1) in the other (patient 6) because of Auer bodies in the blasts, myeloperoxidase, and CD13 and CD33 positivity. No patient had hepatomegaly, lymphoadenopathy, or central nervous system involvement. Only patient 4 had splenomegaly. Leukocytosis was absent or moderate, with only patients 6 and 7 having WBC 450 Â 10 9 /l (Table 1) . Immunophenotyping showed an early pre-B phenotype in patients 1-5 and 8, with data unavailable for patient 9. Patient 7 was considered a biphenotypic leukemia because of myeloperoxidase positivity, but was treated under an ALL protocol.
All patients showed strong CD19 positivity. No expression of cytoplasmic and/or surface immunoglobulin chains was observed in the five cases we tested. CD10 was expressed in both children (patients 5 and 8). Interestingly, in patient 5 the CD10 antigen was found only in a small percentage of blasts. Remarkably, in 7/8 cases we detected expression of CD13 and/or CD33, which are myeloid-related antigens. Two of five children with early pre-B ALL and t(12;17)(p13;q11) described by Krance et al expressed the CD33 antigen and four, like our patient no. 5, expressed CD10 in a subset of blasts. 3 In our patients, an early pre-B ALL phenotype is associated with translocations involving the CIZ gene on 12p13 and coexpression of myeloid-related antigens CD13 and/or Interphase RP11-940J5 and RP11-761J14  ND  ND  ND  ND  ND  1R1G1F 1R1G1F 1R1G1F ND  RP11-369N21 and RP11-101F21 1R1G1F 1R1G1F 1R1G1F 1R1G1F 1R1G1F ND  ND  ND  1R1G1F  RP11-433J6  split  split  split  split  split  split  split  split  split   Metaphase 8.2 der (12) der (17) der (17) der (17) der (17) der (17) der (17) der (22) der (22) der (19) 9.6 der(12) der (12) der (12) der (12) der (12) der (12) der (12) der (12) der (22) der (12) ND ¼ not done, 1R1G1F ¼ one red, one green, and one fusion signal in a range of 20-50% interphase nuclei; split ¼ three signals in 15-54% of interphase nuclei; der(12) ¼ derivative 12 from t(12;17) or t(12;22); der(17) ¼ derivative 17 from t(12;17); der(22) ¼ derivative 22 from t(12;22). CD33. The good response to induction treatments in all our cases with CIZ rearrangements suggests a relatively good prognosis, but since our patients underwent different chemotherapies, no conclusion can be drawn about its prognostic impact. As autologous bone marrow transplantation was successful in patient 1 (Table 1) , it might be a valid approach in this subset of early pre-B ALL. In a consecutive series of 66 adult early pre-B ALL, Cimino et al 4 separated patients with ALL1/AF4 þ or BCR/ABL1 þ from those, like our nine patients, without either fusion gene and observed a significantly better clinical outcome in terms of remission at 3.5 years in the latter group. Interestingly, coexpression of myeloid-related antigens CD13 and/or CD33 was observed in 50% of these patients.
CIZ rearrangements appear to emerge as the genetic marker of a subset of early pre-B ALL without ALL1/AF4 þ or BCR/ABL1 þ that is characterized by the expression of myeloid antigens and reasonably good prognosis. 
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